Keros Therapeutics (NASDAQ:KROS) Rating Lowered to Neutral at Bank of America

Bank of America lowered shares of Keros Therapeutics (NASDAQ:KROS) from a buy rating to a neutral rating in a research report sent to investors on Tuesday morning, MarketBeat reports. Bank of America currently has $18.00 price objective on the stock, down from their prior price objective of $32.00.

Several other equities analysts also recently commented on KROS. Scotiabank cut their price objective on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating on the stock in a research report on Monday, May 12th. Wedbush reaffirmed a “neutral” rating and set a $15.00 price objective on shares of Keros Therapeutics in a research report on Friday, May 30th. Truist Financial dropped their price objective on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. HC Wainwright lowered their price target on Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, May 8th. Finally, Wells Fargo & Company reduced their price objective on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.56.

Keros Therapeutics Stock Down 1.1%

NASDAQ KROS opened at $13.64 on Tuesday. The stock’s 50-day moving average price is $13.74 and its 200-day moving average price is $17.12. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $72.37. The company has a market capitalization of $553.99 million, a P/E ratio of -2.62 and a beta of 1.31.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. During the same quarter in the previous year, the company posted ($1.21) EPS. Research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

Insider Activity

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the firm’s stock in a transaction on Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. The trade was a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 20.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

Hedge funds have recently modified their holdings of the business. ADAR1 Capital Management LLC raised its holdings in Keros Therapeutics by 6,294.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock worth $15,147,000 after purchasing an additional 1,463,215 shares during the last quarter. Braidwell LP raised its holdings in Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock worth $29,989,000 after purchasing an additional 1,187,199 shares during the last quarter. Federated Hermes Inc. raised its holdings in Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock worth $12,474,000 after purchasing an additional 1,099,519 shares during the last quarter. Vanguard Group Inc. raised its holdings in Keros Therapeutics by 31.1% during the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock worth $26,151,000 after purchasing an additional 609,212 shares during the last quarter. Finally, Lynx1 Capital Management LP acquired a new position in Keros Therapeutics during the fourth quarter worth $8,612,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.